PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells

L. Sun; Y. Shi; G. Wang; X. Wang; S. Zeng; S. E. Dunn; G. D. Fairn; Y. J. Li; D. E. Spaner

doi:10.1038/leu.2017.162

PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells

L. Sun, Y. Shi, G. Wang, X. Wang, S. Zeng, S. E. Dunn, G. D. Fairn, Y. J. Li, D. E. Spaner

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARδ but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARδ agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARδ inhibitors. Functional consequences of PPARδ- mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARδ modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARδ antagonists may have therapeutic activity as anti-leukemic signal transduction modulators.

Original language	English
Pages (from-to)	184-193
Number of pages	10
Journal	Leukemia
Volume	32
Issue number	1
DOIs	https://doi.org/10.1038/leu.2017.162
Publication status	Published - Jan 2018
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by CIHR grant MOP1304, CIHR grant MOP 110952, the Leukemia and Lymphoma Society of Canada (DS), CIHR grant MOP133656 (GDF), NSFC (China) grant 81372456 and the Fund for the 8th group of Fostering Talents in Jilin Province of China JRZX8 (Y-JL). LS was supported by the China Scholarship Council (CSC 201506170134). We thank Peppi Prasit (Inception Sciences, San Diego, CA) for NXT1511 and Prof Dr Wibke E Diederich (Center for Tumor Biology and Immunology, Core Facility Medicinal Chemistry, Philipps-Universität Marburg) for DG172.

Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature.

ASJC Scopus Subject Areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2017.162

Cite this

@article{8b9988ff82c343e499f79a7be9fc9796,

title = "PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells",

abstract = "A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARδ but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARδ agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARδ inhibitors. Functional consequences of PPARδ- mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARδ modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARδ antagonists may have therapeutic activity as anti-leukemic signal transduction modulators.",

author = "L. Sun and Y. Shi and G. Wang and X. Wang and S. Zeng and Dunn, {S. E.} and Fairn, {G. D.} and Li, {Y. J.} and Spaner, {D. E.}",

note = "Funding Information: This work was supported by CIHR grant MOP1304, CIHR grant MOP 110952, the Leukemia and Lymphoma Society of Canada (DS), CIHR grant MOP133656 (GDF), NSFC (China) grant 81372456 and the Fund for the 8th group of Fostering Talents in Jilin Province of China JRZX8 (Y-JL). LS was supported by the China Scholarship Council (CSC 201506170134). We thank Peppi Prasit (Inception Sciences, San Diego, CA) for NXT1511 and Prof Dr Wibke E Diederich (Center for Tumor Biology and Immunology, Core Facility Medicinal Chemistry, Philipps-Universit{\"a}t Marburg) for DG172. Publisher Copyright: {\textcopyright} 2018 Macmillan Publishers Limited, part of Springer Nature.",

year = "2018",

month = jan,

doi = "10.1038/leu.2017.162",

language = "English",

volume = "32",

pages = "184--193",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells

AU - Sun, L.

AU - Shi, Y.

AU - Wang, G.

AU - Wang, X.

AU - Zeng, S.

AU - Dunn, S. E.

AU - Fairn, G. D.

AU - Li, Y. J.

AU - Spaner, D. E.

N1 - Funding Information: This work was supported by CIHR grant MOP1304, CIHR grant MOP 110952, the Leukemia and Lymphoma Society of Canada (DS), CIHR grant MOP133656 (GDF), NSFC (China) grant 81372456 and the Fund for the 8th group of Fostering Talents in Jilin Province of China JRZX8 (Y-JL). LS was supported by the China Scholarship Council (CSC 201506170134). We thank Peppi Prasit (Inception Sciences, San Diego, CA) for NXT1511 and Prof Dr Wibke E Diederich (Center for Tumor Biology and Immunology, Core Facility Medicinal Chemistry, Philipps-Universität Marburg) for DG172. Publisher Copyright: © 2018 Macmillan Publishers Limited, part of Springer Nature.

PY - 2018/1

Y1 - 2018/1

N2 - A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARδ but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARδ agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARδ inhibitors. Functional consequences of PPARδ- mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARδ modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARδ antagonists may have therapeutic activity as anti-leukemic signal transduction modulators.

AB - A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARδ but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARδ agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARδ inhibitors. Functional consequences of PPARδ- mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARδ modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARδ antagonists may have therapeutic activity as anti-leukemic signal transduction modulators.

UR - http://www.scopus.com/inward/record.url?scp=85035022892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035022892&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.162

DO - 10.1038/leu.2017.162

M3 - Article

C2 - 28555083

AN - SCOPUS:85035022892

SN - 0887-6924

VL - 32

SP - 184

EP - 193

JO - Leukemia

JF - Leukemia

IS - 1

ER -

PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this